NeuPath Health (NPTH) Q3 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 earnings summary
12 Nov, 2026Executive summary
Q3 2026 revenue was $22.339M and net income was $226,000, versus $22.079M revenue and a $94,000 net loss in Q3 2025; 9M revenue was $67.083M and net income was $2.282M.
Operated 13 medical facilities across Ontario and Alberta, with ~160 healthcare professionals and clinic, physician-staffing and clinical-research services.
Financial highlights
Q3 revenue rose 1% to $22.339M; Adjusted EBITDA was $1.388M versus $1.464M, including $0.2M in physician recruitment costs.
9M revenue was $67.083M, up 3% as reported; Adjusted EBITDA was $4.554M versus $4.970M, down 8% as reported.
Excluding the $1.9M prior-year payment, 9M 2025 revenue was $63.2M and Adjusted EBITDA was $4.4M; 9M 2026 Adjusted EBITDA increased 4% on that basis.
Q3 patient visits rose 7% YoY; clinic revenue was $21.231M versus $20.787M, while non-clinic revenue was $1.108M versus $1.292M.
9M 2026 net income included a $706,000 income tax recovery, versus $400,000 tax expense in 9M 2025.
Outlook and guidance
Nine physicians added in 2026 are expected to contribute more as their practices develop; six recent onboardings are expected to add revenue in Q4, with fuller impact in Q1 and Q2 2027.
No additional physicians are expected to start in 2026; the 2027 goal is roughly two additions per quarter, subject to availability and timing.
Q4 visits are expected to grow, supported by Guelph, new physicians and productivity gains from Heidi and Mika; Guelph may take a year to reach good operating capacity.
Growth plans include physician recruitment, improved facility utilization, new locations and services, and selective clinic acquisitions and adjacent medical services.
Latest events from NeuPath Health
- Physician recruitment and AI productivity underpin plans for nationwide pain-care expansion.NPTH
Planet MicroCap Showcase: Toronto 2026 - H1 revenue and adjusted EBITDA grew alongside higher clinic utilization.NPTH
Investor presentation - Q2 2026 revenue rose 7% to $23.2M, with EBITDA growth, record patient visits, and share buybacks.NPTH
Q2 2026 - Strong revenue growth and expanding physician capacity drive value in a fragmented pain care market.NPTH
2026 Bloom Burton & Co. Healthcare Investor Conference - Q2 2024 revenue up 11% year-over-year, gross margin at 20.0%, net debt down 37%.NPTH
Q2 2024 - Q3 2024 revenue and adjusted EBITDA both rose 9% year-over-year, with improved capacity and lower net debt.NPTH
Q3 2024 - Revenue and adjusted EBITDA rose year-over-year, with new growth investments and clinical milestones.NPTH
Q4 2024 - Record revenue and margin growth in Q1 2025, with new financing and leadership for future expansion.NPTH
Q1 2025 - Record revenue and EBITDA growth driven by clinic optimization and new procedure uptake.NPTH
Q2 2025